Antibody Research at Taylor & Francis
Make your research go further with F1000
Antibody Validations Gateway on F1000Research
Launched in conjunction with CiteAb, the Antibody Validations Gateway on F1000Research provides a platform for researchers and companies to publish their antibody validation studies regardless of the outcome and look up existing validation articles.
YCharOS Gateway on F1000Research
In collaboration with leading antibody manufacturers and knockout cell line providers, YCharOS has developed an antibody characterization platform that enables the systematic comparison of antibody performance of antibodies for western blot, immunoprecipitation, and immunofluorescence.
About F1000
F1000 provides innovative open access publishing Platforms offering rapid publication and open peer review, whilst supporting data deposition and sharing for the research community. F1000’s own publishing Platform, F1000Research combines the ability to publish openly with functionality to ensure transparency, robustness, and reproducibility of research. F1000 partners with leading research funders, learned societies, and institutions, including the Wellcome Trust, the Bill & Melinda Gates Foundation and the European Commission.
More from Taylor & Francis:
mAbs
Affiliated with the Antibody Society, mAbs is a multidisciplinary, open access journal dedicated to the art and science of antibody research and development, covering topics including targets relevant to cancer and immune-mediated disorders, and antibody therapeutics. Find out more.
Impact Factor 2023: 5.6
CiteScore: 10.7
Usage: 1.3M annual downloads/views